Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batoclimab in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05581199Phase 2Terminated
- Sponsor
- Immunovant, Inc.
- Start
- Dec 2022
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial of batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) (4 arms), sponsored by Immunovant, Inc. Primary endpoint: Proportion of participants who remain relapse-free at 36 weeks. Started Dec 2022; status: terminated.
02
Drugs
batoclimab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT05581199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581199.